Alliance Pharma PLC has granted options to its directors under the Long-Term Incentive Plan 2019. Peter Butterfield, the Chief Executive Officer, has been awarded 851,666 share options. Andrew Franklin, the Chief Financial Officer, has been awarded 568,866 share options. Jeyan Heper, the Chief Operating Officer, has been awarded 861,111 share options, 250,000 of which were awarded when he joined the company earlier this year. The options have been granted at no cost and will become exercisable on October 4, 2026, subject to continued employment and the satisfaction of performance conditions based on EPS, TSR, and ROCE targets. The total number of options held by each director is detailed in the news release.